secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vyome Holdings, Inc (HIND)
CIK:        0001427570
Form:       8-K
Filed at:   2026-01-28T23:59:59+00:00
Accession:  0001213900-26-008575
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vyome VT-1953 valuation: $455M rNPV, potential $1.086B after Phase 3
--------------------------------------------------------------------

- Independent report values VT-1953 at $455M rNPV in H1 2026, growing to $1.086B post-Phase 3 in H1 2028.
- No FDA-approved therapies for malignant fungating wounds; 56.5% probability of approval assumed.
- Peak net sales imply $2.2B TAM in 2026, $2.8B by 2040; 30% market share modeled.
- Pricing $20/gram ($9,125/month); Phase 3 starts Q3 2026, NDA and launch targeted Q4 2028.
- Development costs to 2028 estimated at $10M; potential partners include BMS and Pierre Fabre.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427570/000121390026008575/0001213900-26-008575-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427570/000121390026008575/ea0274367-8k_vyome.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-008575

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer